Goran Davidovic, Violeta Iric - Racionalna primena beta-blokatora.pps
WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance...
-
Upload
marlene-cobb -
Category
Documents
-
view
217 -
download
0
Transcript of WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance...
![Page 1: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/1.jpg)
1
WORKING WITH THIRD-PARTY VENDORS AND STRATEGIC PARTNERS
Pharmaceutical Regulatory and Compliance CongressOctober 2008 -- Washington, D.C.
David Davidovic, Senior Director, Business Practices, GenentechPaul Silver, Managing Director, Huron Consulting Group
![Page 2: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/2.jpg)
2
The information presented and discussed represents the opinions
of the authors/presenters and, although descriptive of general
activities, do not necessarily reflect the views of either Genentech or
Huron Consulting Group.
![Page 3: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/3.jpg)
3
Track Objectives
To review the issues involved in working with third- party vendors, consultants and other strategic partners in the development and execution of business activities
To provide practical ideas, tools and techniques to work with external partners to ensure prevention, detection and correction of compliance risks
The scope of third parties: agencies, consultants, meeting planners, medical writers, strategy partners, CROs and others
![Page 4: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/4.jpg)
4
Why This Topic Is Important: Third-party vendors and strategic
partners: Are present in almost every aspect of a
company’s business Are an extension of your business, and
sometimes of your identity – often indistinguishable to the casual observer
Are acting on your behalf Can help your company manage risk…but
they can also put your company at risk
![Page 5: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/5.jpg)
5
The Landscape
![Page 6: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/6.jpg)
6
A Few Realities:
Variable vendor management capabilities: Procuring, on-boarding, managing
People experience and turnover rate: Yours and third-parties’
Competitive pressures: To act rapidly, to out-do
Ever evolving requirements: Federal & state laws, Industry codes,
institutional policies Disclosure & transparency
![Page 7: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/7.jpg)
7
Polling Question (Ask Yourself…) Do you regularly train third-party
vendors, agencies, etc. as part of your compliance training program?A. Regularly (at least once per year)B. Occasionally proactive (e.g. at on-
boarding)C. Reactively: As part of audit corrective
plans, CIAs, etc.D. Never or almost never
![Page 8: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/8.jpg)
8
Some Critical Questions:
For what reason are you hiring them? What are your and their expectations? What should be in the contracts and
agreements? Who is actually going to be doing the work? Whose policies and guidelines should apply? Should you have to train the third-party?
How much? How often? How will you ensure
management/supervision & accountability?
![Page 9: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/9.jpg)
9
Some Critical Questions:
Are there privacy and confidentiality protections?
How will you handle privileged communications?
When & how will you do performance evaluations?
How will corrective actions be implemented?
What are the consequences of non-compliance?
![Page 10: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/10.jpg)
10
Some Ways To Mitigate Risk:
Have clear and comprehensive agreements with duties/obligations and representations/warranties spelled out
Limit number of vendors/partners better ability to monitor and manage
Conduct pilots before fully committing Seek long-term partnerships / limit vendor
turnover Ensure vendors have standards of conduct,
policies, SOPs Have clear data & records expectations:
timeliness, data integrity, retention
![Page 11: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/11.jpg)
11
Some Ways To Mitigate Risk:
Implement initial and ongoing training: “Vendor day”, testing
Have a regular communication and issue-resolution plan
Conduct appropriate monitoring and auditing
Conduct regular business performance evaluations (two-way)
Ensure roles and responsibilities are clearly defined: Who does what; who is accountable for what
Consider sub-certification and assurances (like SOX): Formal and/or informal
![Page 12: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/12.jpg)
12
EFFECTIVE PARTNERSHIP, CONTRACTS AND
AGREEMENTS:GOOD FOR BUSINESS, GOOD
FOR COMPLIANCE
![Page 13: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/13.jpg)
13
Our Sessions For Today
![Page 14: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/14.jpg)
14
Due Diligence Monitoring and Auditing of Third-Party Vendors
Diana Borges, Compliance Manager, Teva North America
Brian Dahl, Director of Compliance, Teva Pharmaceuticals
Michele Girdharry, Manager, Huron
Consulting Group
Paul Silver, Managing Director, Huron Consulting Group
![Page 15: WORKING WITH THIRD- PARTY VENDORS AND STRATEGIC PARTNERS Pharmaceutical Regulatory and Compliance Congress October 2008 -- Washington, D.C. David Davidovic,](https://reader035.fdocuments.net/reader035/viewer/2022062421/56649d9c5503460f94a85d3e/html5/thumbnails/15.jpg)
15
Robust Agreements and Vendor Training: When, Where and How
Janis Crum, Esq., Associate Director of Auditing, Genentech
Mark DeWyngaert, PhD, Managing Director, Huron Consulting Group
Ned Kelly, MD, Vice President, Pharmacovigilance, Quintiles